Iphayiphi

I-R&D ye-Sorrento igxile ekushayeleni okusha ku-COVID-19, ukwelashwa komdlavuza, ukulawula izinhlungu ngokugcwele kanye nezifo ezizimele.

Izinhlelo Ezibalulekile Isiboniso Ukucabangela Isigaba I Phase II Isigaba III/Esibalulekile Ukugunyazwa kwe-FDA
Izinhlelo ze-COVID-19  

COVISTIX™ (ukuxilonga) Rapid Antigen Test

*

Ukugunyazwa Kokusetshenziswa Kwezimo Eziphuthumayo (EUA) e-Mexico (COFEPRIS), Brazil (ANVISA), kanye ne-CE Emakwe eYurophu

I-COVIMARK™ (ukuxilonga) Rapid Antigen Test

*

Isicelo sithunyelwe e-US nase-Canada Sokugunyazwa Ukusetshenziswa Kwezimo Eziphuthumayo (EUA)

COVISHIELD™ (ukwelashwa) I-Neutralizing Antibody (IN) Ezigulini Ezingaphandle Neziguli Ezilaliswayo

40%*

COVISHIELD™ (ukwelashwa) I-Neutralizing Antibody (IV) Ezigulini Ezingaphandle Neziguli Ezilaliswayo

20%*

FUJOVEE™ (Abivertinib) I-COVID-19 enzima ezigulini zase-ICU

82%*

Isivivinyo Esibalulekile Esisalindile I-FDA Clearance

OQORY™ (COVI-MSC) I-ARDS ngenxa ye-COVID-19 ezigulini zase-ICU

82%*

Isivivinyo Esibalulekile eBrazil

MPro Inhibitor (iphilisi lomlomo) Anti-viral

40%*

Umgomo we-Omicron mRNA Umgomo

20%*

Izinhlelo Ezibalulekile Isiboniso Ukucabangela Isigaba I Phase II Isigaba III/Esibalulekile Ukugunyazwa kwe-FDA
immunotherapy  

FUJOVEE™ (Abivertinib) I-NSCLC

82%*

FUJOVEE™ (Abivertinib) I-B Cell Lymphomas

60.2%*

FUJOVEE™ (Abivertinib) I-Prostate

20%*

FUJOVEE™ (Abivertinib) Lupus

20%*

FUJOVEE™ (Abivertinib) MS

20%*

FUJOVEE™ (Abivertinib) I-GvHD

20%*

I-PD-L1 (Socazolimab)* I-SCLC

82%*

*Ngokubambisana ne-Lee's Pharm e-China

I-PD-L1 (STI-3031)** Umdlavuza wesibeletho

82%*

**E-US futhi ngokubambisana ne-ImmuneOncia yaseKorea

I-CD47 Izimila eziqinile

40%*

I-CD38 DAR-T I-Myeloma eminingi

40%*

CD38 ADC I-Amyloidosis, i-Myeloma eminingi, i-T-ALL, ne-esophageal

40%*

I-TROP2 ADC* Izimila eziqinile

40%*

* E-China

I-Seprehvec™ oncolytic virus Izimila eziqinile; Izicubu ze-CNS

40%*

I-BCMA ADC Izimila Liquid

20%*

I-Bevacizumab-ADAB™ Umdlavuza we-Endometrial

40%*

Ngokubambisana neMayo Clinic

I-Bevacizumab-ADAB™ Cancer wesibeletho

40%*

Ngokubambisana neMayo Clinic

I-Rituximab-ADAB™ I-B-cell Lymphomas

40%*

Ngokubambisana neMayo Clinic
Izinhlelo Ezibalulekile Isiboniso Ukucabangela Isigaba I Phase II Isigaba III/Esibalulekile Ukugunyazwa kwe-FDA
Ubuhlungu  

I-ZTlido™ 1.8%
I-Postherpetic Neuralgia - PHN

99.8%*

I-SP-102 (SEMDEXA) I-Lumbar Radicular / Sciatica Pain

82%*

I-SP-103 (I-Lidocaine Topical System 5.4%) Ubuhlungu Obubuhlungu Emuva

20%*

I-SP-104 (I-Naltrexone Yokuqhunyiswa Ebambezelekile) fibromyalgia

20%*

I-RTX (resiniferatoxin)
Umjovo we-epidural
Ubuhlungu Obungalawuleki Kumdlavuza Othuthukile

60.3%*

Igama lentandane

I-RTX (resiniferatoxin)
Umzila we-Intra-articular
Ubuhlungu Bedolo Obuphakathi Kuya Kunzima

60.2%*

Izinhlelo Ezibalulekile Isiboniso Ukucabangela Isigaba I Phase II Isigaba III/Esibalulekile Ukugunyazwa kwe-FDA
Ukulethwa kwe-Lymphatic  

Sofusa® elwa ne-TNF I-Autoimmune (RA)

40%*

Sofusa® i-anti-PD-1 I-Cutaneous T-Cell Lymphoma (CTCL)

40%*

Sofusa® anti-CTLA-4 I-Melanoma

40%*

Ngokubambisana neMayo Clinic
Izinhlelo ze-COVID-19
Izinhlelo Ezibalulekile (Inkomba) Isigaba
COVISTIX™ (ukuxilonga) I-FDA EUA
I-COVIMARK™ (ukuxilonga) I-FDA EUA
COVISHIELD™ (ukwelashwa) PH I
COVISHIELD™ (ukwelashwa) Ukucabangela
FUJOVEE™ (Abivertinib) Ph III
OQORY™ (COVI-MSC) Ph III
I-Mpro Inhibitor (iphilisi lomlomo) (anti-viral) Ph I
Umgomo we-Omicron mRNA (umuthi wokugoma) Ukucabangela
immunotherapy
Izinhlelo Ezibalulekile (Inkomba) Isigaba
I-FUJOVEE™ (Abivertinib) (NSCLC) Ph III
I-FUJOVEE™ (Abivertinib) (B Cell Lymphomas) Ph II
I-FUJOVEE™ (Abivertinib) (Prostate) Ukucabangela
I-FUJOVEE™ (Abivertinib) (I-Lupus) Ukucabangela
I-FUJOVEE™ (Abivertinib) (MS) Ukucabangela
I-FUJOVEE™ (Abivertinib) (GvHD) Ukucabangela
I-PD-L1 (Socazolimab)*(SCLC) Ph III
I-PD-L1 (STI-3031)** (Umdlavuza wesibeletho) Ph III
I-CD47 (Izimila Eziqinile) Ph I
I-CD38 DAR-T (I-Myeloma eminingi) Ph I
CD38 ADC (I-Amyloidosis, i-Myeloma eminingi, i-T-ALL, ne-esophageal) Ph I
I-TROP2 ADC* (Izimila Eziqinile) Ph I
I-Seprehvec™ oncolytic virus (Izimila Eziqinile; CNS Tumors) PH I
I-BCMA ADC (Amathumba Amanzi) Ukucabangela
I-Bevacizumab-ADAB™ (Umdlavuza we-Endometrial) Ph I
I-Bevacizumab-ADAB™ (Umdlavuza wesibeletho) Ph I
I-Rituximab-ADAB™ (B-cell Lymphomas) Ph I
Ubuhlungu
Izinhlelo Ezibalulekile (Inkomba) Isigaba
I-ZTlido™ 1.8% (I-Postherpetic Neuralgia - PHN) Ukugunyazwa kwe-FDA
I-SP-102 (SEMDEXA) Ph III
I-SP-103 (I-Lidocaine Topical System 5.4%) Ukucabangela
I-SP-104 (I-Naltrexone Yokuqhunyiswa Ebambezelekile) Ukucabangela
I-RTX (resiniferatoxin) umjovo we-epidural (Ubuhlungu obungalawuleki kuCancer Osezingeni eliphezulu) Ph II
I-RTX (resiniferatoxin) Umzila we-intra-articular (Ubuhlungu bedolo obuphakathi ukuya kuye obunzima) Ph II
Ukulethwa kwe-Lymphatic
Izinhlelo Ezibalulekile (Inkomba) Phase II
Sofusa® elwa ne-TNF (I-Autoimmune RA) Ph I
Sofusa® i-anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I
Sofusa® anti-CTLA-4 (I-melanoma) Ph I